{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:10:21Z","timestamp":1780791021699,"version":"3.54.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T00:00:00Z","timestamp":1617148800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Japanese Gastric Cancer Association"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gastric Cancer"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s10120-021-01179-4","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T19:03:01Z","timestamp":1617217381000},"page":"1131-1139","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["QOL assessment after palliative surgery for malignant bowel obstruction caused by peritoneal dissemination of gastric cancer: a prospective multicenter observational study"],"prefix":"10.1007","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4692-3110","authenticated-orcid":false,"given":"Yuichi","family":"Ito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Fujitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kentaro","family":"Sakamaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiko","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryohei","family":"Kawabata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Tanizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaki","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanobu","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motohiro","family":"Hirao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Hihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoji","family":"Fukushima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Choda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Kodera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Teshima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisashi","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,3,31]]},"reference":[{"key":"1179_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"1179_CR2","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1056\/NEJMoa072252","volume":"357","author":"S Sakuramoto","year":"2007","unstructured":"Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810\u201320.","journal-title":"N Engl J Med"},{"key":"1179_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-012-0163-4","volume":"16","author":"A Nashimoto","year":"2013","unstructured":"Nashimoto A, Akazawa K, Isobe Y, Miyashiro I, Katai H, Kodera Y, et al. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer. 2013;16:1\u201327.","journal-title":"Gastric Cancer"},{"key":"1179_CR4","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1159\/000218355","volume":"32","author":"D Gencer","year":"2009","unstructured":"Gencer D, Kastle-Larralde N, Pilz LR, Weiss A, Buchheidt D, Hochhaus A, et al. Presentation, treatment, and analysis of prognostic factors of terminally ill patients with gastrointestinal tumors. Onkologie. 2009;32:380\u20136.","journal-title":"Onkologie"},{"key":"1179_CR5","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S0002-9610(98)00323-7","volume":"177","author":"TJ Miner","year":"1999","unstructured":"Miner TJ, Jaques DP, Tavaf-Motamen H, Shriver CD. Decision making on surgical palliation based on patient outcome data. Am J Surg. 1999;177:150\u20134.","journal-title":"Am J Surg"},{"key":"1179_CR6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1001\/jamasurg.2013.4059","volume":"149","author":"TJ Paul Olson","year":"2014","unstructured":"Paul Olson TJ, Pinkerton C, Brasel KJ, Schwarze ML. Palliative surgery for malignant bowel obstruction from carcinomatosis: a systematic review. JAMA Surg. 2014;149:383\u201392.","journal-title":"JAMA Surg"},{"key":"1179_CR7","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.ejso.2018.12.015","volume":"45","author":"NL de Boer","year":"2019","unstructured":"de Boer NL, Hagemans JAW, Schultze BTA, Brandt-Kerkhof ARM, Madsen EVE, Verhoef C, et al. Acute malignant obstruction in patients with peritoneal carcinomatosis: the role of palliative surgery. Eur J Surg Oncol. 2019;45:389\u201393.","journal-title":"Eur J Surg Oncol"},{"key":"1179_CR8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"EuroQol","year":"1990","unstructured":"EuroQol. A new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199\u2013208.","journal-title":"Health Policy"},{"key":"1179_CR9","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1097\/00005650-199711000-00002","volume":"35","author":"P Dolan","year":"1997","unstructured":"Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35:1095\u2013108.","journal-title":"Med Care"},{"key":"1179_CR10","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3109\/07853890109002087","volume":"33","author":"R Rabin","year":"2001","unstructured":"Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med. 2001;33:337\u201343.","journal-title":"Ann Med"},{"key":"1179_CR11","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/S0959-8049(00)00417-2","volume":"37","author":"CW Vickery","year":"2001","unstructured":"Vickery CW, Blazeby JM, Conroy T, Arraras J, Sezer O, Koller M, et al. Development of an EORTC disease-specific quality of life module for use in patients with gastric cancer. Eur J Cancer. 2001;37:966\u201371.","journal-title":"Eur J Cancer"},{"key":"1179_CR12","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1016\/j.ejca.2004.05.023","volume":"40","author":"JM Blazeby","year":"2004","unstructured":"Blazeby JM, Conroy T, Bottomley A, Vickery C, Arraras J, Sezer O, et al. Clinical and psychometric validation of a questionnaire module, the EORTC QLQ-STO 22, to assess quality of life in patients with gastric cancer. Eur J Cancer. 2004;40:2260\u20138.","journal-title":"Eur J Cancer"},{"key":"1179_CR13","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/j.1572-0241.2002.05423.x","volume":"97","author":"DG Adler","year":"2002","unstructured":"Adler DG, Baron TH. Endoscopic palliation of malignant gastric outlet obstruction using self-expanding metal stents: experience in 36 patients. Am J Gastroenterol. 2002;97:72\u20138.","journal-title":"Am J Gastroenterol"},{"key":"1179_CR14","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1007\/s00464-005-0454-5","volume":"20","author":"G Navarra","year":"2006","unstructured":"Navarra G, Musolino C, Venneri A, De Marco ML, Bartolotta M. Palliative antecolic isoperistaltic gastrojejunostomy: a randomized controlled trial comparing open and laparoscopic approaches. Surg Endosc. 2006;20:1831\u20134.","journal-title":"Surg Endosc"},{"key":"1179_CR15","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","volume":"240","author":"D Dindo","year":"2004","unstructured":"Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240:205\u201313.","journal-title":"Ann Surg"},{"key":"1179_CR16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","volume":"250","author":"PA Clavien","year":"2009","unstructured":"Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250:187\u201396.","journal-title":"Ann Surg"},{"key":"1179_CR17","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1016\/j.ejca.2011.06.002","volume":"47","author":"PC Thuss-Patience","year":"2011","unstructured":"Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, et al. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer\u2013a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO). Eur J Cancer. 2011;47:2306\u201314.","journal-title":"Eur J Cancer"},{"key":"1179_CR18","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1200\/JCO.2011.39.4585","volume":"30","author":"JH Kang","year":"2012","unstructured":"Kang JH, Lee SI, Lim DH, Park KW, Oh SY, Kwon HC, et al. Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol. 2012;30:1513\u20138.","journal-title":"J Clin Oncol"},{"key":"1179_CR19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1470-2045(13)70549-7","volume":"15","author":"HE Ford","year":"2014","unstructured":"Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014;15:78\u201386.","journal-title":"Lancet Oncol"},{"key":"1179_CR20","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461\u201371.","journal-title":"Lancet"},{"key":"1179_CR21","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1634\/theoncologist.2009-0057","volume":"14","author":"DS Chi","year":"2009","unstructured":"Chi DS, Phaeton R, Miner TJ, Kardos SV, Diaz JP, Leitao MM Jr, et al. A prospective outcomes analysis of palliative procedures performed for malignant intestinal obstruction due to recurrent ovarian cancer. Oncologist. 2009;14:835\u20139.","journal-title":"Oncologist"},{"key":"1179_CR22","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.amjsurg.2008.09.030","volume":"198","author":"C Schmidt","year":"2009","unstructured":"Schmidt C, Gerdes H, Hawkins W, Zucker E, Zhou Q, Riedel E, et al. A prospective observational study examining quality of life in patients with malignant gastric outlet obstruction. Am J Surg. 2009;198:92\u20139.","journal-title":"Am J Surg"},{"key":"1179_CR23","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1002\/bjs5.26","volume":"1","author":"K Fujitani","year":"2017","unstructured":"Fujitani K, Ando M, Sakamaki K, Terashima M, Kawabata R, Ito Y, et al. Multicentre observational study of quality of life after surgical palliation of malignant gastric outlet obstruction for gastric cancer. BJS Open. 2017;1:165\u201374.","journal-title":"BJS Open"}],"container-title":["Gastric Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-021-01179-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10120-021-01179-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10120-021-01179-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:06:16Z","timestamp":1648685176000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10120-021-01179-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,31]]},"references-count":23,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1179"],"URL":"https:\/\/doi.org\/10.1007\/s10120-021-01179-4","relation":{},"ISSN":["1436-3291","1436-3305"],"issn-type":[{"value":"1436-3291","type":"print"},{"value":"1436-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,31]]},"assertion":[{"value":"3 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"M. Ando reports grants from Kyowa Kirin Co. Ltd., outside the submitted work. T. Yoshikawa reports personal fees from Ono Pharmaceutical Co., Ltd., personal fees from MSD K.K., personal fees from Eli Lilly Japan K.K., personal fees from Taiho Pharmaceutical Co., Ltd., personal fees from Chugai Pharmaceutical Co., Ltd., personal fees from Nippon Kayaku Co., Ltd., personal fees from Bristol-Myers Squibb, personal fees from Daiichi Sankyo Co., Ltd., personal fees from TERUMO Co., personal fees from Johnson & Johnson K.K., personal fees from Pfizer Inc., personal fees from Olympus Co., personal fees from Yakult Honsha Co., personal fees from Eisai Co., personal fees from Kyowa Hakko Kirin Co., Ltd., personal fees from Covidien Japan Co., Ltd., outside the submitted work. T. Yamada reports personal fees from Ono Pharmaceutical Co., Ltd., personal fees from Bristol-Myers Squibb, personal fees from Taiho Pharmaceutical Co., Ltd., outside the submitted work. Fukushima reports grants from Ono Pharmaceutical Co., Ltd., grants from Taiho Pharmaceutical Co., Ltd., grants from Chugai Pharmaceutical Co., Ltd, outside the submitted work. Kodera reports grants and personal fees from Taiho Pharmaceutical Co., Ltd., grants and personal fees from Chugai Pharmaceutical Co., Ltd., grants and personal fees from Takeda Pharmaceutical Co., Ltd., grants from MSD K.K., grants from Nippon Kayaku Co., Ltd., grants and personal fees from Yakult Honsha Co., grants and personal fees from Eli Lilly Japan K.K., grants and personal fees from Ono Pharmaceutical Co., Ltd., grants from Kaken Pharmaceutical Co., Ltd., grants and personal fees from Covidien Japan Co., Ltd., grants from EA Pharma\u3000Co., grants from Novartis Pharma K.K., grants from KCI K.K., grants from Maruho Co., Ltd., grants from Daiichi Sankyo Co., Ltd., grants and personal fees from Otsuka Pharmaceutical Co., Ltd., grants from TSUMURA & Co., grants from Sawai Pharmaceutical Co., personal fees from Johnson & Johnson K.K., personal fees from MSD K.K., grants from Bristol-Myers Squibb, grants from Sanofi K.K., outside the submitted work. All remaining authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All the procedures were followed in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all patients before being included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}